[1]Xu P, Sauve AA. Vitamin B3, the nicotinamide adenine dinucleotides and aging[J]. Mech Ageing Dev, 2010, 131(4):287-298.
[2]Heitzer T, Wenzel U, Hink U, et al. Increased NAD(P)H oxidasemediated superoxide production in renovascular hypertension: evidence for an involvement of protein kinase C[J]. Kidney Int, 1999, 55(1):252-260.
[3]Petrelli R, Felczak K, Cappellacci L. NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications[J]. Curr Med Chem,2011, 18(13):1973-1992.
[4]Zhang R. MNADK, a long-awaited human mitochondrion-localized NAD kinase[J]. J Cell Physiol, 2015,230(8):1697-1701.
[5]Zhang R. MNADK, a novel liver-enriched mitochondrion-localized NAD kinase[J]. Biol Open,2013, 2(4):432-438.
[6]Ohashi K, Kawai S, Murata K. Identification and characterization of a human mitochondrial NAD kinase[J]. Nat Commun, 2012, 3:1248.
[7]Kahn K, Finkel A. It is a tumor——current review of headache and brain tumor[J]. Curr Pain Headache Rep, 2014, 18(6):421.
[8]Woodworth GF, Dunn GP, Nance EA, et al. Emerging insights into barriers to effective brain tumor therapeutics[J]. Front Oncol, 2014, 4:126.
[9]Pollak N, Niere M, Ziegler M. NAD kinase levels control the NADPH concentration in human cells[J]. J Biol Chem, 2007, 282(46):33562-33571.
[10]Lerner F, Niere M, Ludwig A, et al. Structural and functional characterization of human NAD kinase[J]. Biochem Biophys Res Commun, 2001, 288(1):69-74.
[11]Houten SM, Denis S, Te Brinke H,et al. Mitochondrial NADP(H) deficiency due to a mutation in NADK2 causes dienoyl-CoA reductase deficiency with hyperlysinemia[J]. Hum Mol Genet, 2014, 23(18):5009-5016.
[12]Cea M, Cagnetta A, Fulciniti M, et al. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition[J]. Blood, 2012, 120(17):3519-3529. |